NASDAQ
0.88USD
+0.02 (+2.50%)
We have scored 3 news catalysts on Citius Oncology, Inc. (CTOR) over the past 12 months. The biggest single-day move next to one of them came Jan 5, 2026, when CTOR closed +6.5%: “SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)”. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in revenue growth rate and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
81.6M
P/E
—
EPS
—
Beta
3.53
52W range
0.491-2.25
Day range
0.85–0.89
Open
0.89
Prev close
0.86
Volume
136.1
Avg volume
81K
Dividend
0.00
IPO
2022-12-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Citius Oncology, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CTOR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
